高血压和高血压合并冠状动脉疾病患者的左心功能

对３２例高血压和高血压合并冠状动脉疾病（ＣＡＤ）的患者应用γ心功能仪做了左心功能测定。结果表明，高血压患者和左心室射血分数（ＬＶＥＦ）明显高于正常人和高血压合并ＣＡＤ的患者（６２．４±９．２ｖｓ５１．７±６．８，Ｐ〈０．０５，６２．４±９．９ｖｓ４２±１５，Ｐ〈０．０１）。高血压与正常人组其高峰充盈率（ＰＦＲ）差别不显著（２．４５±０．５２ｖｓ２．２７±０．４５，Ｐ〉０．０５），而高血压合并ＣＡＤ     

地奥心血康对心肌缺血再灌注犬心功能及去甲肾上腺素含量的影响

２８只杂种犬分地奥心血康组（ＤＡＸＸＫ）和生理盐水组（ＮＳ）。结扎冠状动脉左前降支使心肌缺血。分别于结扎即刻静脉滴注ＤＡＸＸＫ（５．０ｍｇ／ｋｇ）和１００ｍｌＮＳＮ。ＮＳ组随缺血再灌时间延长，ＣＩ，ＬＶＳＰ，±ｄｐ／ｄｔｍａｘ等明显下降，而ＴＰＶＲ与血清Ｌｅｖ含量进行性升高。ＤＡＸＸＫ与ＮＳ比较，有显改善心功能的效应。     

地奥心血康对心肌缺血再灌注犬心功能及去甲肾上腺素含量的影响

２８只杂种犬分地奥心血康组（ＤＡＸＸＫ）和生理盐水组（ＮＳ）。结扎冠状动脉左前降支使心肌缺血。分别于结扎即刻静脉滴注ＤＡＸＸＫ（５．０ｍｇ／ｋｇ）和１００ｍｌＮＳ。ＮＳ组随缺血再灌注时间延长，ＣＩ，ＬＶＳＰ，±ｄＰ／ｄｔｍａｘ，等明显下降，而ＴＰＶＲ与血清Ｌｅｖ含量进行性升高。ＤＡＸＸＫ与ＮＳ比较，有显著改善心功能的效应。     

兔蓝斑兴奋引起动脉血压升高

目的：研究电刺激和化学刺激兔蓝斑（ＬＣ）对动脉血压（ＡＰ）和肾交感神经传出活动（ＲＳＡ）的影响。方法：电刺激ＬＣ，ＬＣ微量注射Ｌ－Ｇｌｕ、盐酸吗啡、ＧＡＢＡ、电解毁损ＬＣ，记录ＡＰ和ＲＳＡ。结果：电刺激ＬＣ和ＬＣ注射Ｌ－Ｇｌｕ均引起ＡＰ升高分别为１３．５±０．３ｖｓ１９．５±０．８ｋＰａ和１３．８±０．４ｖｓ１７．５±０．８ｋＰａ）和ＲＳＡ增加。ＬＣ注射吗啡、ＧＡＢＡ对ＡＰ和ＲＳＡ无明显影响。电解     

果糖二磷酸钠辅助治疗冠心病

目的：观察果糖二磷酸钠（ＦＤＰ，１，６－二磷酸果糖）治疗冠心病的疗效。方法：５４例住院确诊冠心病病人（男性３９例，女性１５例；年龄６６±ｓ１０ａ）在常规药物治疗的同时每日加用ＦＤＰ５～１０ｇ，连续用药４ｗｋ，为ＦＤＰ组。另有相似６６例（男性４４例，女性２２例；年龄６７±１１ａ）在常规药物治疗同时加用葡萄糖－胰岛素－氯化钾（ＧＩＫ）注射液５００ｍＬ，静脉滴注，ｑｄ，连续用药４ｗｋ，为ＧＩＫ组，进行比较。结果：ＦＤＰ组临床总有效率８５％优于ＧＩＫ组５９％（Ｐ＜０．０５）。ＦＤＰ组治疗后ＳＶ，ＣＯ，ＬＶＥＦ，ＦＳ有明显升高（Ｐ＜０．０１或Ｐ＜０．０５），而ＧＩＫ组无此效应；ＦＤＰ组无毒副作用。结论：ＦＤＰ为治疗冠心病的安全、有效的辅助药物。     

尼莫地平防治蛛网膜下腔出血后迟发性脑血管痉挛

目的：观察尼莫地平注射液防治蛛网膜下腔出血（ＳＡＨ）后迟发性脑血管痉挛（ＤＣＶＳ）的疗效。方法：将６０例ＳＡＨ病人随机分为尼莫地平组（男性２０例，女性１０例，年龄５４±ｓ６ａ）和对照组（男性２１例，女性９例，年龄５５±５ａ）各３０例。２组均于发病７２ｈ内接受治疗，对照组用脱水、止血等常规疗法，尼莫地平组在常规疗法基础上加用尼莫地平注射液５０ｍＬ（含１０ｍｇ），静脉滴注，ｑｄ×１４ｄ。结果：尼莫地平组ＤＣＶＳ发生率和ＳＡＨ死亡率明显低于对照组（Ｐ＜０．０５）；再出血发生率２组无明显差异（Ｐ＞０．０５）。结论：尼莫地平注射液预防ＳＡＨ后ＤＣＶＳ疗效确切，且无增加再出血的危险。     

甘草酸三铵盐对兔胸注动脉条收缩反应的影响

甘草酸三铵盐（ＴＡＧＡ）非竞争性对抗去甲肾上腺素（ＮＡ）和氯化钾（ＫＣｌ）对离休兔胸主动脉条的收缩效应，ＰＤ２（ＮＡ）＝６．２４２６±０．３５０８，ＰＤ’２（ＴＡＧＡ）＝１．７８４４±０．３６４５。ＴＡＧＡ同时促进低浓度ＫＣｌ（１０ｍＭｏｌ／Ｌ）收缩动脉条件作用，表现为双向作用。ＴＡＧＡ使ＮＡ所致动脉条收缩发生舒张，且作用持久。在给ＫＣｌ之前，先给ＴＡＧＡ，ＴＡＧＡ抑制ＫＣｌ的收缩作用。     

反义BCR-ABL寡核苷酸对化疗药物体外净化白血病细胞的增强效应

目的研究反义寡核苷酸对化疗药物阿霉素（ＡＤＭ）、足叶乙甙（ＶＰ－１６）及阿糖胞苷（Ａｒａ－Ｃ）体外抑制Ｋ５６２细胞克隆形成的影响，并探讨其可能的作用机制。方法体外甲基纤维素半固体培养观察各处理组Ｋ５６２细胞的克隆形成，流式细胞仪评价细胞的凋亡状况。结果实验浓度下单独应用ＡＤＭ、ＶＰ－１６或Ａｒａ－Ｃ，Ｋ５６２细胞集落存活率分别为４１．４１％、５０．２８％及５２．０８％，先用反义寡核苷酸ＡＳ－ｂ３ａ２处理，再用上述３种化疗药物，集落存活率则分别为１５．２０％、１９．７７％及２１．３２％（Ｐ＜０．０１）；单独应用ＡＳ－ｂ３ａ２，Ｋ５６２集落存活率为３９．３１％，流式细胞仪检测到ＡＳ－ｂ３ａ２处理后的Ｋ５６２凋亡细胞比例为２７．２％，联用ＡＤＭ后凋亡细胞比例为４６．２０％，而未处理组仅为７．４％。结论实验结果提示，反义ＢＣＲ－ＡＢＬ寡核苷酸ＡＳ－ｂ３ａ２能增强化疗药物ＡＤＭ、ＶＰ－１６或Ａｒａ－Ｃ对Ｋ５６２细胞克隆形成的抑制作用，其作用可能在于增强化疗药物体外诱导Ｋ５６２细胞的凋亡。     

复方新诺明和甲氧等氨嘧啶对丁胺卡那霉素药代动力学的影响

本文利用ＦＰＩＡ法测定了家兔丁胺卡那霉素单用与ＳＭＺ－ＴＭＰ或ＴＭＰ合用时的药代动力学变化。结果测得单用时Ｋｅ＝０．０１０８±０．００１３ｍｉｎ＾－１，Ｔ１／２＝６５．８９±７．３０ｍｉｎ，ＡＵＣ＝０．２９０８±２７８．０３ｍｉｎ．μｇ／ｍｌ，Ｔｐｅａｋ＝２９．９４±１１．０６ｍｉｈ，ＣＬ／ｆ（ｓ）＝０．０００６７９０±０．０００１４６ｌ／ｋｇ．ｍｉｎ；（Ⅱ）与ＳＭＺ－ＴＭＰ合用时ＫＥ＝０．００９     

尾加压素Ⅱ对血管平滑肌细胞增殖的影响

目的研究体内新发现的缩血管活性肽尾加压素Ⅱ（ｕｒｏｔｅｎｓｉｎ Ⅱ, Ｕ Ⅱ）对大鼠主动脉平滑肌细胞增殖作用的影响以及ＵⅡ作用的细胞内信号转导机制。方法在培养的大鼠主动脉平滑肌细胞（ＡＳＭＣ）上,采用［３Ｈ］－胸腺嘧啶（［３Ｈ］－ＴｄＲ）参入法,观察 ＵⅡ对细胞 ＤＮＡ合成的刺激作用;加入不同的细胞内信号转导阻断剂,观察对ＵⅡ效应的影响。结果 Ｉ× １０－９～ １× １０－７ ｍｏｌ·Ｌ－１ ＵⅡ以浓度依赖方式促进 ＡＳＭＣ［３Ｈ］－ＴｄＲ参入增加, １× １０－９、１× １０－８和 １×１０－７ｍｏｌ·Ｌ－１ＵⅡ组［３Ｈ］－ＴｄＲ参入量分别较对照组增加２２％（Ｐ＜０．０５）,５７％（Ｐ＜０,０１）和６５％（Ｐ＜０．０１）。ＵⅡ的效应能被钙通道阻断剂尼卡地平、ＰＫＣ阻断剂Ｈ７、钙调素激酶（ＣａＭ－ＰＫ）阻断剂 Ｗ７和 ＭＡＰＫ阻断剂 ＰＤ９８０５９所阻断,抑制率分别为５５％（Ｐ＜０．０１）,２７％（Ｐ＜０．０１）,１８％（Ｐ＜０．０５）和１６％（Ｐ＜０．０５）。结论 ＵⅡ是一种新发现的强烈的促ＡＳＭＣ增生的内源性丝裂原,其促丝裂效应可能通过Ｃａ２＋、ＰＫＣ、ＣａＭ－ＰＫ和ＭＡＰＫ来介导。     

The ocular surface side effects of an anti-psychotic drug,clozapine

Purpose: The purpose of this study is to investigate the effects of long-term clozapine usage on tear film stability and corneal topographic parameters.

Material and methods: The study was conducted between March 2014 and November 2014. Thirty patients who were diagnosed of schizophrenia and have been under clozapine treatment for 2.73?±?0.73 years (range 2–4 years) were involved in this study (group 1). Thirty healthy subjects (group 2) who have statistically similar demographic features compared with the group 1, were involved as a control group. Full ophthalmologic examination with biomicroscopy and indirect ophthalmoscopy was applied. Corneal topographic parameters were measured using the Pentacam HR and Schirmer test was done. Statistical analysis of the subjects was evaluated by using SPSS (for Windows version 16.0; SPSS Inc., Chicago, IL) program.

Results: K₁ value was measured as 43.39?±?0.17?D (43–43.50?D) and K₂ value was measured as 43.39?±?0.06?D (43.30–43.50?D) in groups 1 and 2, respectively. In groups 1 and 2, K₂ values were noted as 43.86?±?0.27?D (43.50–44.50?D) and 43.72?±?0.18?D (43.50–44.00?D), respectively. Central corneal thickness was found to be 523.93?±?15.66?µm (495–554?µm) and 550.13?±?1.03?µm (520–580?µm) in groups 1 and 2, respectively. Corneal apex thickness was 525.86?±?15.75?µm (497–556?µm) in group 1 and 551.60?±?14.99?µm (521–581?µm) in group 2. The corneal thickness of thinnest location was 520.93?±?15.60?µm (492–551?µm) and 548.06?±?15.17?µm (518–578?µm) in groups 1 and 2, respectively. Corneal volume was determined as 58.13?±?3.46?mm³ (52–64?mm³) in group 1 and 60.73?±?3.76?mm³ (54–66?mm³) in group 2. The Schirmer test showed thichkness of 3.33?±?0.72?mm (2–4?mm) and 13.60?±?1.59?mm (11–16?mm) in groups 1 and 2, respectively. The mean fluorescein break-up time was 5.40?±?1.50?s (3–8?s) and 12.46?±?1.40?s (10–14?s) in groups 1 and 2, respectively. There was a statistically significant difference in the Schirmer test, fluorescein break-up time, central corneal thickness, corneal apex, and the thinnest corneal location thickness between the two groups.

Conclusion: Clozapine may induce dry eye syndrome and thus may lead to morphological alterations in corneal parameters through its anticholinergic and antidopaminergic activities. Because of these corneal alterations, one should be aware of evaluating patients having diseases like glaucoma or preoperative selection of corneal refractive surgery candidates.     

经皮椎体后凸成形术治疗老年椎体后壁完整的重度骨质疏松性椎体压缩骨折的效果

目的 探讨经皮椎体后凸成形术(PKP)治疗老年椎体后壁完整的重度骨质疏松性椎体压缩骨折(OVCF)的临床效果.方法 回顾性分析2012年1月至2014年1月于本院诊治的47例(54个椎体)OVCF患者临床资料,所有患者均采用球囊扩张复位法进行PKP治疗,治疗后随访18～24个月.对比患者治疗前、后及末次随访时患椎高度、疼痛度评分(VAS)、局部Cobb角及健康调查评分(SF-36),观察临床治疗效果.结果 47例患者治疗前患椎平均高度为(8.4±1.3) mm、VAS评分为(7.9±1.8)分、局部Cobb角为(25.1±5.5)°、SF-36评分为(33.2±6.5)分;治疗后3d患椎平均高度为(12.8±1.9)mm、VAS评分为(2.3±1.1)分、局部Cobb角为(17.2±4.5)°、SF-36评分为(44.5±6.8)分;末次随访患椎平均高度为(12.3±2.1) mm、VAS评分为(2.4±1.3)分、局部Cobb角为(18.3±4.7)°、SF-36评分为(46.3±7.1)允治疗后3d及末次随访数据与治疗前比较差异均具有统计学意义(均P＜0.05),治疗后3d与末次随访数据比较差异无统计学意义(P＞0.05).结论 OVCF患者采用球囊扩张复位法行PKP治疗,安全性高,临床效果明显.     

重组人表皮生长因子滴眼液在全激光经角膜上皮的角膜切削术术后疗效观察

目的 观察重组人表皮生长因子滴眼液在全激光经角膜上皮的角膜切削术(TransPRK)术后的临床疗效观察.方法 选取行TransPRK手术60例病人(120只眼),采用硬币法分成观察组和对照组.观察组在常规用药的基础上加用重组人表皮生长因子滴眼液(用药频次为4次每天,1次1滴,时间为持续1周),对照组常规用药.术后于第1天、第2天、第3天、第1个月、第2个月、第3个月时分别评价疼痛、异物感、角膜上皮愈合情况、裸眼视力、角膜上皮下雾状混浊(Haze)、残余等效球镜度(MRSE)指标.结果 除Haze指标外,其它指标的时间点观察值均差异有统计学意义(P<0.05).两组间疼痛、角膜上皮愈合在第2天、第3天差异有统计学意义(P<0.008 3,α'=0.05/6=0.008 3),观察组评分均低于对照组评分;裸眼视力指标在第2天、第3天差异有统计学意义(P<0.008 3,α'=0.008 3),且观察组评分(4.40±0.12)、(4.83±0.12)均高于对照组评分(4.33±0.12)、(4.76±0.14);其它观察指标均差异无统计学意义.结论 重组人表皮生长因子滴眼液能够改善TransPRK术后病人的早期部分疼痛症状,能够促进角膜上皮的愈合,提高早期视力,对异物感、Haze、MRSE均无影响.     

单侧与双侧入路经皮椎体后凸成形术治疗胸腰椎体压缩性骨折的近期疗效对比

目的 探究单侧与双侧入路经皮椎体后凸成形术(PKP)治疗胸腰椎体压缩性骨折病人的近期疗效.方法 选取徐州市铜山区人民医院2018年2月至2019年6月收治的92例胸腰椎体压缩性骨折病人,采用随机数字表法分为两组,各46例.观察组行单侧入路PKP治疗,对照组行双侧入路PKP治疗.对比两组视觉模拟评分法(VAS)评分、椎体及Cobb角恢复度、骨水泥量及渗漏率、透视次数和手术时间情况.结果 两组术前、术后VAS评分的差异无统计学意义(P>0.05),观察组、对照组术后3个月的VSA评分分别为(2.54±0.51)分、(2.65±0.42)分,均低于术前(7.38±1.96)分、(7.25±2.01)分(P<0.05).两组椎体前缘、中间恢复高度及Cobb角恢复度、骨水泥渗漏率之间差异无统计学意义(P>0.05).观察组手术时间为(24.18±6.83)min,短于对照组(34.58±7.14)min;透视次数为(16.17±4.05)次,少于对照组(27.69±4.28)次;骨水泥量为(4.38±1.04)mL,少于对照组(5.22±1.17)mL(均P<0.05).结论 单侧或双侧入路PKP治疗胸腰椎体压缩性骨折病人均可有效缓解疼痛感,纠正脊柱后凸畸形,而单侧入路PKP的手术时间更短,并可减少放射暴露.     

Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema

Objective: To evaluate anatomical and functional outcomes of intraviteal bevacizumab (IVB) in patients with chronic diabetic macular edema (DME), and the effectivity and safety of dexamethasone implant in those unresponsive to regular IVB treatment. Methods: Thirty-five eyes of 35 patients (16 male and 19 female) with chronic DME (central foveal thickness (CFT) >?275?μm, duration >?6 months) received three injections of 2.5?mg IVB with six-week intervals. At 18 weeks, dexamethasone implant was applied to patients unresponsive to IVB. Main outcomes were the change in best corrected visual acuity (BCVA), CFT and ocular and systemic adverse effects for both drugs. The patients responsive to IVB were followed up for 36 weeks and those patients receiving dexamethasone implant were followed up for 24 weeks postoperatively. Results: At 18 weeks, the mean BCVA (0.68?±?0.40 logMAR, p?=?0.45) and CFT (453?±?169?μm, p?=?0.58) did not show any significant change compared to baseline (0.74?±?0.42 logMAR and 521?±?151?μm, respectively). In 20 patients (%57.1) responsive to IVB, the CFT was significantly improved from 12 to 36 weeks with the mean value of 295?±?42 μ (p?=?0.01). However, no significant difference was observed for BCVA during this period (p?=?0.17). Dexamethasone was implanted in 15 eyes (42.8%) unresponsive to IVB at 18 weeks. Statistically significant improvements were observed in BCVA (at postoperative 4 and 12 weeks) and CFT (at postoperative 4, 12 and 24 weeks). In addition, both parameters significantly worsened at 24 weeks compared to 12 weeks (p?<?0.001 and p?=?0.01, respectively). Conclusions: Patients with chronic DME should be followed in accordance with a fixed treatment protocol combining anti-VEGF and steroid treatments.     

微小 RNA-15a-5p靶向蛋白质二硫键异构酶 A6前体蛋白抑制前列腺癌细胞增殖、迁移及侵袭

目的 探讨微小RNA-15a-5p(miR-15a-5p)是否可通过靶向蛋白质二硫键异构酶A6前体蛋白(PDIA6)而抑制前列腺癌细胞增殖、迁移及侵袭.方法 选取2018年2月至2019年3月江南大学附属医院接受治疗的前列腺癌病人50例,采用实时荧光定量PCR(qRT-PCR)与蛋白印迹法(Western blotting)分别检测前列腺癌组织、癌旁组织中miR-15a-5p、PDIA6的表达量;体外培养人前列腺癌DU145细胞,将细胞分为miR-NC组、miR-15a-5p组、si-NC组、si-PDIA6组、miR-15a-5p+pcDNA组、miR-15a-5p+pcDNA-PDIA6组;噻唑蓝(MTT)检测细胞增殖;Transwell小室实验检测细胞迁移及侵袭;双荧光素酶报告实验验证miR-15a-5p、PDIA6的靶向关系.结果 与癌旁组织相比,前列腺癌组织中miR-15a-5p的表达水平降低[(1.00±0.17)比(0.68±0.11)],PDIA6 mRNA[(0.99±0.09)比(1.64±0.18)]和蛋白[(0.44±0.07)比(0.76±0.17)]表达水平升高;转染miR-15a-5p mimics或转染si-PDIA6可降低细胞存活率(P<0.05),减少迁移及侵袭细胞数(P<0.05);双荧光素酶报告实验证实miR-15a-5p可靶向结合PDIA6;PDIA6过表达可降低miR-15a-5p过表达对DU145细胞增殖、迁移及侵袭的抑制作用.结论 过表达miR-15a-5p通过降低PDIA6的表达对列腺癌细胞增殖、迁移及侵袭能力有抑制作用.     

准分子激光角膜切削术治疗近视术后2年疗效观察

回顾分析经ＰＲＫ治疗的１０２例病人１７３只眼术后２年的屈光改变，根据术前屈光度将病人分为低度，中度和高度近视眼组。术后最短随访时间为２年，用Ｈｏｌｌａｄａｙ，Ｃｒａｖｙ，Ｋｏｃｈ矢量分析法评价术后１、３、６个月和１、２年屈光改变。结果：３组１７３只眼中有１５９只眼（９１．９９％）接受１次ＰＲＫ治疗，２只眼（１．２％）接受２次治疗，１０只眼（５．８％（接受３次治疗，２只眼（１．２％），接受４次治疗。     

改良Frosch入路与传统前外侧入路治疗后外侧胫骨平台骨折的效果分析

目的 比较改良Frosch入路与传统前外侧入路在治疗后外侧胫骨平台骨折方面的疗效,评价改良Frosch入路在治疗后外侧胫骨平台骨折中的安全性、实用性及有效性。方法 通过分析2020年1月至2022年6月就诊于安徽医科大学附属宿州医院因后外侧胫骨平台骨折行手术治疗的56例病例资料,其中采用改良Frosch入路的病人29例,作为观察组。传统前外侧入路的病人27例,作为对照组。手术均由同一位医生完成。对手术时间、术中出血量、骨折愈合时间、术前疼痛强度、末次随访时疼痛强度、术后3、6个月膝关节功能,术后3、6个月膝关节屈伸活动度、术后相关并发症发生进行分析。结果 观察组手术时间（117.00±1.25）min明显较对照组（132.52±1.12）min更快,差异有统计学意义（P<0.05）;观察组术中出血量（108.97±2.41）mL少于对照组术中出血量（136.85±1.63）mL,差异有统计学意义（P<0.05）;观察组骨折愈合时间（4.53±0.05）月稍快于对照组（4.64±0.05）月,差异无统计学意义（P>0.05）;术前及末次随访时疼痛强度观察组与对照组相比,...     

超声定量参数结合骨折风险预测简易工具预测绝经后骨质疏松症病人骨折风险

目的探讨超声定量参数结合骨折风险预测简易工具( FRAX)对绝经后骨质疏松症( OP)病人骨折风险的预测效能。方法选取河南省直第三人民医院 2020年 1月至 2021年 10月收治的绝经后 OP病人 139例和绝经后健康志愿者 141例,分别记为疾病组与对照组。两组均采用超声检查并进行 FRAX评价。比较两组超声定量参数［包括超声声速( SOS)、信号强度( SI)和宽带超声衰减( BUA)］、 FRAX结果、双能 X线骨密度仪测量结果骨密度 T分值( T-score)、随访 1年内的骨折发生率。绘制受试者操作特征曲线( ROC曲线)分析超声定量参数结合 FRAX对病人骨折风险的预测效能,并与 T-score比较。结果疾病组 SOS、 SI、BUA和 T-score均低于对照组［( 1 496.45±70.25)m/s比( 1 569.83±79.98)m/s,(64.32±11.06)%比( 90.08±9.85)%,(51.38±7.02) dB/MHz比( 71.65±9.12)dB/MHz,(2.85±0.17)SD比( 0.62±0.11)SD］(P<0.05), FRAX(4.05±0.71比 0.85±0.17)和骨折发生率(19.42%比 2.84%)均高于对照组(均 P<0.05);疾病组骨折发生病人年龄、身体质量指数(BMI)均高于骨折未发生病人, OP病程长于骨折未发生病人(均 P<0.05);疾病组骨折发生者 SOS、SI、BUA和 T-score均低于骨折未发生者［( 1 348.82±69.85)m/s比(1 532.04±74.63)m/s,(40.68±8.39)%比( 70.02±10.25)%,(35.33±6.01)dB/MHz比( 55.25±8.16)dB/MHz,( 3.85±0.19)SD比(2.61±0.10)SD］,FRAX高于骨折未发生者( 8.99±1.05比 2.86±0.53)(均 P<0.05);超声定量参数联合 FRAX预测疾病组骨折发生的灵敏度均高于单独预测、 T-score预测,曲线下面积( AUC)也高于单独预测、 T-score预测( P<0.05),特异度高于 T-score预测。结论绝经后 OP病人超声 SOS、SI、BUA下降, FRAX结果和骨折风险升高,且超声 SOS、SI、BUA结合 FRAX可预测骨折风险,且优于 T-score预测。     

l -Deprenyl metabolism by the cytochrome P450 system in monkey (Cercopithecus aethiops) liver microsomes

1. The aim was to clarify the kinetic and cytochrome P450 (CYP) enzymes involved in l -deprenyl metabolism by liver microsomal preparations from African green monkeys, an animal model extensively used in the study of Parkinson's disease. 2. CYP levels and monoxygenase activities were similar to those observed in microsomes from other monkey strains. The enzyme kinetics of both l -methamphetamine and l -nordeprenyl formation were characterized by a high- and low-affinity component. For l -methamphetamine, the apparent K m 1 and K m 2 were 1.07 ±0.01 and 350 ±2.7 µM, and V max 1 and V max 2 were 4.70 ±0.01 and 8.9 ±0.02 nmol min <1 mg protein <1, respectively. For l -nordeprenyl, K m 1 and K m 2 were 0.96 ±0.05 and 168 ±15 µM, and V max 1 and V max 2 were 3.34 ±0.02 and 3.91 ±0.02 nmol min <1 mg protein <1, respectively The ratio V max / K m for both metabolites was 2 orders of magnitude higher for the low K m component than for the high K m, suggesting that the former component is the major determinant of l -deprenyl N-dealkylation. At 15 µM l -deprenyl, both ketoconazole and 8-methoxypsoralen significantly inhibited l -methamphetamine and l -nordeprenyl formation, indicating that CYP3A and CYP2A enzymes were involved in both reactions. At 500 µM l -deprenyl, however, inhibition studies suggest the involvement of CYP1A and 2D enzymes. 3. The metabolism of l -deprenyl by monkey liver microsomes is very efficient, indicating that CYP-dependent metabolism is relevant and could contribute to neuroprotection in primate models of Parkinson's disease.